Icosavax (ICVX) Stock Price, News & Analysis

Company Overview

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key Stats

• Today's Range: $15.31 to $15.31
• 50-Day Range: $15.31 to $15.45
• 52-Week Range: $4.75 to $16.10
• Volume: N/A
• Average Volume: 1.22 million shs
• Market Capitalization: $766.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ICVX Stock Analysis - Frequently Asked Questions

How were Icosavax's earnings last quarter?

Icosavax, Inc. (NASDAQ:ICVX) released its quarterly earnings results on Monday, November, 15th. The company reported ($1.30) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.81. The firm earned $1.83 million during the quarter, compared to the consensus estimate of $3.30 million.

When did Icosavax IPO?

Icosavax (ICVX) raised $150 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

What other stocks do shareholders of Icosavax own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Icosavax investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ICVX
• CIK: 1786255
• Web: icosavax.com
• Phone: 206-737-0085
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-91,760,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -43.06%
• Return on Assets: -39.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.06
• Quick Ratio: 18.06

Sales & Book Value

• Annual Sales: $580,000.00
• Price / Sales: 1,322.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.47 per share
• Price / Book: 2.80

Miscellaneous

• Outstanding Shares: 50,090,000
• Free Float: 34,767,000
• Market Cap: $766.88 million
• Optionable: Optionable
• Beta: 1.28